Serina Therapeutics, Inc. (SER) - Cash on Hand per Share

Serina Pharma - graphic logo of issuer SER

Serina Therapeutics, Inc. (SER) is developing a polymer drug delivery system for the treatment of neurological pathologies. The current cash per share, with GURU.Markets data illustrated on this chart, equals 0.72. This is supported by the implementation of POZ technology for rare injections and the availability of a proprietary, patent-protected POZ-GK platform, although final profit depends on clinical trial results.

Serina (SER) - Cash per Share from 03/28/2024 to 11/21/2026

Comprehensive metric breakdowns and analytics for serinatherapeutics.com (SER)

- market value and analyst target forecast:
- market capitalization indicators:
- cash availability and cash flow indicators:
General company analysis:Serina Therapeutics, Inc. - SER
Product sample of Serina Therapeutics, Inc.

For Serina Therapeutics, Inc. (SER), which develops costly polymer drug delivery technologies, liquidity is critical for sustaining preclinical research. This metric is calculated by dividing total cash reserves by the number of shares outstanding. Analyzing cash per share allows for an assessment of the real value of the liquid collateral backing each security. This determines the company's resilience to market shocks. A high cash level guarantees the issuer's survival during the prolonged development of therapies.